2 min read
Beyond Acceleration: What Priority Review Really Means
In Brazil, priority review is often associated with faster regulatory timelines. However, under the framework established by ANVISA through RDC n° 1001/2025, prioritization is not simply a mechanism for acceleration—it is a regulatory decision based on defined strategic criteria.
Not all applications are eligible. Priority is granted selectively, depending on how a product aligns with national health priorities and regulatory objectives.
The Logic Behind Priority Review
Rather than focusing on isolated criteria, the framework reflects a broader regulatory logic. Applications are more likely to qualify when they align with one or more of the following dimensions:
- Public Health Relevance
Medicines addressing serious, neglected, emerging, or life-threatening conditions—particularly where no therapeutic alternatives exist—are central to prioritization decisions. - Unmet Medical Needs
Products targeting specific populations, such as pediatric patients, may be prioritized when existing treatment options are limited or unavailable. - Strategic National Interest
ANVISA places emphasis on strengthening domestic capabilities. Applications involving local development, manufacturing, or participation in public programs such as Productive Development Partnerships (PDPs) may receive priority consideration. - Market Dynamics and Access
Priority may also apply to products that enhance market competition, including first generic or biosimilar entries, particularly when they can improve access or reduce dependency. - Supply Continuity
In situations where there is a risk of shortage, prioritization may be used as a mechanism to support the continuity of supply in the healthcare system.
What This Means for Pharmaceutical Companies
Qualifying for priority review is not a procedural step—it is a strategic positioning exercise.
Companies should consider:
- Whether their product clearly demonstrates public health relevance or unmet need
- How the submission aligns with national priorities, including local development or supply continuity
- The timing of the submission in relation to market dynamics (e.g., first generics or biosimilars)
- Whether the dossier clearly communicates its regulatory and strategic value—not only its technical completeness
Early assessment of these factors can help determine whether pursuing priority review is viable and how to position the submission accordingly.
Key Considerations
Priority review is not automatically granted and does not guarantee approval. Additionally, certain applications—such as those affected by patent protection timelines—may not be eligible for prioritization.
As a result, early evaluation of eligibility criteria and alignment with regulatory priorities becomes critical in defining submission strategies.
Priority review in Brazil is not simply about accelerating timelines—it is about prioritizing impact. Understanding how eligibility is determined under RDC n° 1001/2025 allows companies to better position their submissions, supporting more informed and strategically aligned pathways to approval.
If your organization is evaluating priority review eligibility in Brazil, connect with Freyr’s team to assess your product’s positioning and define a more structured submission pathway.
